Dipeptidyl peptide 4 (DDP-4) inhibitors or gliptins (sitagliptin, saxagliptin, and linagliptin) inhibit glucagon release resulting in reduced blood glucose levels, however significant side effects include increased risk of heart failure, pancreatitis and pancreatic cancer [6]. This evidence concerns the gene GCG and familial pancreatic carcinoma.